Quantcast

Latest National Institute for Health and Clinical Excellence Stories

2008-08-07 18:00:00

By HELEN RAE PATIENTS with advanced kidney cancer will be denied four life- extending treatments on the NHS because they are not cost effective. The National Institute for Health and Clinical Excellence (Nice) yesterday issued draft guidance rejecting the drugs Sutent (Sunitinib), Avastin, Nexavar and Torisel. Charities expressed outrage at the decision, saying it left patients only one treatment option - Interferon - to which many do not respond. Cancer sufferer Ken Potts, 55, of...

2008-08-07 15:00:12

By HELEN PUTTICK HEALTH CORRESPONDENT CHARITIES yesterday spoke out about the NHS refusing patients new treatments for a rare form of cancer. Drugs watchdog for England and Wales, the National Institute for Health and Clinical Excellence (Nice), has ruled four new kidney cancer medicines are effective but do not offer the health service good value for money. In Scotland, equivalent body the Scottish Medicines Consortium (SMC), has already rejected three of the treatments. Cancer...

2008-08-07 12:00:18

PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines published today. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). Charities expressed outrage at the decision, saying it left patients only one treatment option - interferon - to which many do not respond. Professor John Wagstaff, from the...

2008-08-07 12:00:18

By JANE KIRBY Broadcaster James Whale accused a health watchdog today of being "barbaric" in denying kidney cancer patients access to four drugs. The star, who was diagnosed with the disease in 2000 and set up a charity to raise awareness, said the National Institute for Health and Clinical Excellence (Nice) was a "very badly named organisation". He slammed Nice's decision - which is subject to appeal - to deny patients access to Sutent (sunitinib), Avastin (bevacizumab), Nexavar...

2008-08-07 09:01:05

GlaxoSmithKline plans to renegotiate with the UK's Department of Health as part of its attempt to reverse the National Health Service's decision regarding the company's cancer drug Tyverb, reported the Financial Times. According to the news source, GlaxoSmithKline (GSK) is proposing a new 'price-volume' deal to address the concerns of the National Institute for Health and Clinical Excellence (NICE), the government's medicines advisory body, which considers Tyverb as too costly when compared...

2008-08-07 09:10:00

By Barry Nelson PATIENTS with advanced kidney cancer were dealt a devastating blow last night when spending watchdogs effectively banned four life- giving drugs on the NHS. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent, Avastin, Nexavar and Torisel as too expensive. Charities expressed outrage at the decision, saying it left patients only one treatment option ? interferon ? which is not as effective for many sufferers....

2008-07-28 18:00:41

Lord Darzi's recent plan for the NHS may only have concerned England, but his ideas for speeding up the drug appraisals process could have implications for the All Wales Medicines Strategy Group. Health Wales spoke to Professor Philip Routlege, chair of the group about what happens next THE speed at which new breakthrough drugs and treatments are appraised for use on the NHS has long been a thorny issue. Despite devolution and the considerable divergence of health policy between Wales and...

2008-07-08 12:00:16

The medical advisory panel to the UK National Health Service has recommended that GlaxoSmithKline's Tyverb should not be used on the NHS to treat advanced metastatic breast cancer on the grounds that it is not effective enough to justify its cost. This decision represents not only a blow to GSK but also casts doubt on how many other new cancer therapies will be available in the UK. The UK panel ruled that, based on data showing that the median survival time for women who received Tyverb...

2008-07-08 09:00:12

The National Institute of Health and Clinical Excellence has advised against the use of GlaxoSmithKline's oral cancer drug Tyverb in the UK's National Health Service, reported the Financial Times. According to the Financial Times, The National Institute of Health and Clinical Excellence (NICE) has issued a provisional recommendation that Tyverb for advanced breast cancer failed to meet its threshold for clinical and cost effectiveness. GSK tried to negotiate a 'risk-sharing' arrangement...

2008-07-05 00:00:23

THOSE people faced with the threat of losing their sight will rejoice that a treatment is now available on the NHS in Yorkshire which might prevent this terrible prospect. However, this hugely welcome news should not be allowed to erase the memory of the unnecessarily tortuous battle that campaigners have had to fight to reach this major landmark. The National Institute for Health and Clinical Excellence took months to reach a decision over Lucentis, deliberations that culminated in...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related